The American company Pfizer is investigating the possibility of injecting a third dose of its coronavirus vaccine.
This was reported by the press service of the manufacturer.
"Pfizer and BioNTech have begun evaluating the safety and immunogenicity of the third dose of COVID-19 vaccine to understand the impact of the additional dose on immunity from COVID-19 infection caused by the spreading and potential new emerging variants of SARS-CoV-2," it said.
The document says that participants in the first phase of drug testing in the US will be asked to receive an additional 30 micrograms of an additional dose 6-12 months after two standard injections.
"This additional dose study is important for understanding the safety of the third dose and immunity against circulating strains," the company said.
The research will involve about 150 people aged 18-55 and 65-85 years. All of them will be monitored for two years after vaccination.
As previously reported, the South African strain reduced the immune response by two-thirds in people vaccinated with Pfizer.
In addition, scientists found that Pfizer's COVID drug prevents the transmission of coronavirus by 89.4%.